Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business. Read why I think HIMS stock is ...

Hims & Hers has risen 70% since November 2024, outperforming the S&P 500, despite recent regulatory challenges impacting its compounded semaglutide product. Its diversified portfolio in men's and ...

Fact checked by Nick BlackmerFact checked by Nick Blackmer Telehealth prescription company Hims & Hers has a new semaglutide initiative. The program will offer compounded semaglutide to customers ...

In spite of growing scrutiny around compounded versions of semaglutide medications, COO Melissa Baird says Hims & Hers is ...

An ad for compounded versions of weight-loss drug semaglutide by telehealth company Hims & Hers has attracted the ire of a pharmaceutical trade organisation that calls the campaign "nothing short ...

Much of the excitement over Hims & Hers has been connected to the company's sales of compounded versions of GLP-1 inhibitor semaglutide. Novo Nordisk markets semaglutide as a treatment for type 2 ...

The end of the official shortage status for semaglutide came as telehealth company Hims & Hers – which has been pushing sales of compounded semaglutide hard and lambasting the pharma industry ...